A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis

NCT02064816 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis, Relapsing-Remitting

Interventions

DRUG: Rebif®
DRUG: Rebif®

Sponsor

Merck KGaA, Darmstadt, Germany